Fig. 7: TGF-β1 is the key factor that participates the immunosuppression and anti-apoptosis pathways of IL18-hUCMSC in vitro and in vivo. | Cell Death & Disease

Fig. 7: TGF-β1 is the key factor that participates the immunosuppression and anti-apoptosis pathways of IL18-hUCMSC in vitro and in vivo.

From: Interleukin-18-primed human umbilical cord-mesenchymal stem cells achieve superior therapeutic efficacy for severe viral pneumonia via enhancing T-cell immunosuppression

Fig. 7: TGF-β1 is the key factor that participates the immunosuppression and anti-apoptosis pathways of IL18-hUCMSC in vitro and in vivo.The alternative text for this image may have been generated using AI.

A, B The proliferation level of human CD3+ T-cells was analyzed by flow cytometry; the change of CFSE fluorescence intensity indicates the growth ratio (A); and the immunosuppression ratio was analyzed statistically (B). C, D Representative flow cytometric images with Annexin V/7-AAD double staining assay of cells treated with or without PR8 virus (C); Quantification of Annexin V-7AAD- live cells is shown: (Annexin V-7AAD- cell amount / total cell amount) × 100% (D). Human MRC-5 cell line and mouse alveolar epithelial cells were used in apoptosis experiments in vitro. E, F The cell apoptosis in lung tissues was analyzed by flow cytometry, and 7AAD+ cells were regarded as apoptotic cells (E); the percentages of Annexin V-7AAD- live cells in different groups were calculated at 7 dpi (G). Fresolimumab (GC1008) and TGF-β Ab is the blocking reagent that target to TGF beta-1,2,3. Data are shown as mean ± SEM. n = 3–5 in each group. *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant.

Back to article page